|
MolMed gets US FDA Orphan Drug status for malignant mesothelioma drug (PharmaBiz)
MolMed S.p.A announced that the U S Food and Drug Administration has granted Orphan Drug designation for MolMed's investigational new anti-tumour therapeutic drug NGR-hTNF (ARENEGYR) in the treatment of malignant pleural mesothelioma (reference code # 08-2639).
us.rd.yahoo.com
Mesothelioma patient outlines frail condition (Daily Press)
An ex-shipyard worker seeks $15M from a company that he says exposed him to asbestos. John O. Koonce appeared to be in good health when he retired from The Virginian-Pilot four years ago.
us.rd.yahoo.com
Learn About the Pipeline Insight: Cancer Overview-Lung, Brain, Head and Neck, Thyroid (Marketwire via Yahoo! Finance)
Reportlinker.com announces that a new market research report related to the Healthcare industry is available in its catalogue.
us.rd.yahoo.com
LegalView Recounts the Results of a Recent Mesothelioma Study That Reported High Survival Rates Among Patients Taking ... (PRWeb via Yahoo! News)
LegalView reported the results of an Italian study to its mesothelioma blog readers; the results detailed a positive outcome and increased survival rate for elderly pleural mesothelioma victims. The study, recently published in a British medical journal, used a combination of two medicinal treatments commonly prescribed separately.
us.rd.yahoo.com
|
